Ginkgo Bioworks Holdings, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
1218Ginkgo Bioworks Holdings's Business Model
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
About Ginkgo Bioworks Holdings
Website: https://www.ginkgobioworks.com
CEO (Chief Executive Officer): Dr. Jason Kelly
IPO date: 2021-04-19
Contact
Country: US
Address: 27 Drydock Avenue
City: Boston
State: MA
Phone: 877 422 5362
Zip Code: 02210
Other
CIK: 0001830214
ISIN: US37611X1000
CUSIP: 37611X100
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.